GlycoNet is advancing research, innovation, and training in glycomics to improve the quality of life of Canadians.
GlycoNet is a one-stop global destination focused on developing new carbohydrate-based drugs, vaccines and diagnostics, in collaboration with academic and industry organizations to address areas of unmet need through applied glycomics research. This national platform supports translational research, protection of intellectual property, novel drug development, company formation and training of a new generation of glyco-scientists and entrepreneurs. The network includes over 170 researchers across Canada who focus on cancer, chronic diseases, infectious diseases, and neurodegenerative diseases.
GlycoNet is funded by the Government of Canada through the Networks of Centres of Excellence (NCE) Program.
GlycoNet “punches above its weight” in glycomics innovation.
(Institute of Health Economics Report, 2021)
0
Network Investigators
0
Trained HQP
0
Funded Projects
0
Network Partners
Latest News
Enzymes linked with immune cell activity could hold key to better understanding inflammation
Findings show promise for developing potential new anti-inflammatory drugs and treatments for autoimmune diseases.
GlycoNet partner company, Alectos Therapeutics, enters ground-breaking $700 million agreement with Biogen
This collaboration combines Alectos’ expertise in small-molecule therapeutics with Biogen’s development capabilities in movement disorders.
Glycomics is writing the next chapter in bioinnovation
In BIOTECanada’s Insights Magazine, GlycoNet Scientific Director Warren Wakarchuk writes about the importance of glycomics, opportunities to leverage glycomics, and Canadian glycomics expertise.
Quick Links
Glycomics: The New Frontier in BioinnovationUpcoming Events
Canadian Glycomics Network
E5-33 Gunning/Lemieux Chemistry Centre
University of Alberta, T6G 2G2
Tel: 780-492-6204
Fax: 780-492-4147
Subscribe to GlycoNet’s Newsletter
© CANADIAN GLYCOMICS NETWORK (GLYCONET). ALL RIGHTS RESERVED.
English 
French